HR Execs on the Move

OrthoTennessee

www.orthotn.com

 
OrthoTennessee provides the finest orthopedic clinics in East Tennessee, improving lives through patient-centered care, orthotics, therapy and imaging.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.orthotn.com
  • 256, Fort Sanders West Boulevard
    Knoxville, TN USA 37922
  • Phone: 865.769.4500

Executives

Name Title Contact Details

Similar Companies

UPM Pharmaceuticals

UPM Pharmaceuticals is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Twin Boro Physical Therapy

With 42 locations in 10 New Jersey counties, Twin Boro Physical Therapy could not be more convenient! Our skilled physical therapists match the proper techniques with each patients ailment and body.

TWG Market Research

TWG Market Research is a Barrington, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Serán Bioscience,

Serán Bioscience is a contract development and manufacturing organization (CDMO) that provides drug development services to the pharmaceutical industry, including chemistry, formulation, spray drying, dosage form, analytical, and GMP manufacturing serv...

Artios Pharma

Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced leadership team with world class scientific capabilities and proven expertise in DDR drug discovery, including the identification and development of the PARP inhibitor olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and The Francis Crick Institute, London. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers which will move into Phase 1 clinical studies in 2021. These include ATR inhibitor ART0380 for treating DDR defective tumours and the first-in-class Pol theta inhibitor ART4215 for mono therapy and combination treatments. In December 2020, Artios entered into a global three-year strategic research collaboration with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Artios is backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with an office in New York City, USA.